Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients For patients received initial dose over 3 months, the ORR is 80.6% and for patients received...

Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC

Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Studies (Presentation: #259P) NUTLEY, N.J., Sept. 10, 2022 /PRNewswire/ -- Eisai announced today results...

Multi-Biomarker Approach Achieves 61 Percent Sensitivity for Cancer at an Overall Specificity of 98.2 Percent in Robust Case-Control Study Including Nearly 600 Cancer Samples Data will Inform the...

Aktiia leveraged its data set of more than 55m data points to demonstrate that hypertensive individuals who use the Aktiia 24/7 cuffless monitor persistently for six months achieve a significant...